INTRODUCTION
The use of air purifiers is rapidly increasing due to increases in fine dust and respiratory diseases. Particulate matter with an aerodynamic diameter of 2.5 μm or less (PM2.5) is a principal component of indoor air pollution in homes and is a major cause of asthma exacerbation and lung dysfunction. With people spending most of their time indoors nowadays, there has been increasing interest in the practical effect of using air purifiers to improve indoor air pollution.

In South Korea, a recent study suggested that air purifiers may improve the severity of atopic dermatitis by reducing air pollutants and fine particles. However, no studies have analyzed the effects of air purifiers on children with asthma in South Korea. According to a recent study in Fresno, CA, air purifiers are effective in reducing indoor PM2.5 and significantly improve symptoms and peak flow rates in children with allergic diseases. However, the study was limited by the small number of study subjects and a very low basal PM2.5 levels in the city where the study was conducted. Also, recent evidence has indicated that microbial diversity and phthalate can exacerbate asthma.

The purpose of this study was to evaluate the control of indoor air quality through the use of air purifier actually and its effects on Korean children with asthma. This study measured PM2.5 levels, asthma severity, lung function, and urine microbiome and phthalate concentrations.

Effects of Indoor Air Purifiers on Children with Asthma
Ga Hee Lee¹, Jeong Hee Kim¹,², Sungroul Kim³,⁴, Sangwoon Lee³,⁴, and Dae Hyun Lim¹,²
¹Department of Pediatrics, School of Medicine, Inha University, Incheon;
²Environmental Health Center for Allergic Disease, Inha University Hospital, Ministry of Environment, Incheon;
³Department of Environmental Health Sciences, Soonchunhyang University, Asan;
⁴Integrated Research Center for Risk Assessment, Soonchunhyang University, Asan, Korea.

Purpose: To evaluate the effects of air purifiers on the concentrations of indoor air pollutants and on asthma control in children.

Materials and Methods: In this randomized crossover trial, daily use of an air purifier filter was compared with a matched placebo with the filter off. Thirty elementary school students who had asthma were enrolled and randomly allocated to one of two groups. The primary endpoints were changes in indoor air quality, asthma severity, lung function, airway inflammatory, urine microbiome, and phthalate after the installation of air purifiers. PM2.5 and CO2 were measured as indoor air pollutants. Asthma severity was assessed in terms of both symptom and medication scores acquired using a daily questionnaire. The higher the score, the better the symptom or the less frequent the use of medication. Peak expiratory flow rate and fractional exhaled nitric oxide were also measured.

Results: The mean age of the enrolled patients was 9.2±1.98 years. The mean concentration of PM2.5 was 17.0 μg/m3 in the filter-off condition, but significantly lower at 9.26 μg/m3 in the filter-on condition. Medication scores were 6.9 for the filter-off and 7.12 for the filter-on conditions, reflecting a statistically significant decrease in the frequency of medications used during air purifier operation. Bacterial richness, as determined using the Chao 1 index, was markedly lower in the filter-on than the filter-off condition.

Conclusion: This study suggests that air purifiers benefit medication burden in children with asthma by reducing PM2.5 levels.

Key Words: Asthma, air purifier, indoor air pollutants, fractional exhaled nitric oxide, urine microbiome, children
MATERIALS AND METHODS

Patients and study setting
The participants consisted of elementary school students who were living in cities in the Incheon and Gyeonggi-do regions and who had been diagnosed with asthma at Inha Hospital. The diagnosis was determined according to the GINA guidelines.8 This study was conducted as a randomized, single-blind, cross-over study between September 3 and October 27, 2018 with a 2-week wash out period.

Inclusion/exclusion criteria
The inclusion criteria comprised at least two periods of asthma exacerbation in the last year. We excluded children who had been born during gestational week 34 or earlier, children with a birth weight of 2.5 kg or lower, children with a congenital deformity, children with immune dysfunction, and cases where consent to participate was not given.

Intervention
A total of 30 asthma patients were randomly allocated to Group A (n=15) or Group B (n=15) (Fig. 1). The 30 households participating in the study installed an air purifier (TOWER XQ; Winix, Siheung, South Korea) in the living room, where the children spent most of their time. Participants were instructed to use the air purifier 24 hours per day, every day, for 6 weeks. The air purifiers operated normally throughout the study period, without any problems. Group A used the air purifier with a filter for the first 3 weeks, while Group B used the air purifier without a filter during that time, so that it did not provide any actual function. Following a 2-week filter change period, the groups were changed over the next 3 weeks (Supplementary Table 1, only online).

Outcome measurement
We compared indoor PM2.5, carbon dioxide (CO2) concentration, relative humidity, and temperature before and after air purifier use. We also examined whether there were any changes in asthma symptoms and frequency of medication use. To compare lung function and airway inflammation, we measured peak expiratory flow rate (PEFR) and fractional exhaled nitric oxide (FeNO). In addition, we analyzed changes in microbes and phthalate metabolites in urine.

Indoor air quality
Indoor air quality data, including PM2.5, CO2, temperature, relative humidity, were obtained using ESCORT (ESCORT, Asan, Korea). PM2.5 concentrations were measured through a laser-light scattering sensor at 2-minute intervals in each household’s main living space. Then, to match our health symptom data, we calculated daily mean values. We also evaluated the performance of a real-time PM2.5 sensor, compared with the US EPA Federal Equivalent Method.9

Asthma control questionnaire
To objectively measure symptom improvements and changes in medication use after air purifier use, we had the participants complete the asthma control questionnaire every day. The asthma control questionnaire used in this study was based on the Test for Respiratory and Asthma Control in Kids (TRACK)10 (Supplementary Tables 2 and 3, only online). The response to each question was scored, with higher scores indicating greater improvement in symptoms and a lower frequency of medication use.

Lung function test
We used PEFR as surrogate marker for lung function. The PEFR measurement was performed using Smart One® (Medical International Research; Roma, Italy). Portable measuring instruments were distributed to the study subjects, and measurements were taken three times each morning and evening, the highest value of which was recorded. Measurements were linked to mobile phone applications, and data were extracted for each follow-up visit.

Airway inflammatory test
We used FeNO as a surrogate marker for airway inflammation. FeNO was measured at each follow-up visit using NIOX MINO® (Aerocrine, Solna, Sweden). To do so, the participant was asked to sit in a chair and, while wearing a nose plug, in-
Isolation of microbiome extracellular vesicles and DNA extraction from urine

Two milliliters of voided clean catch midstream urine were collected and stored at -20°C. To isolate the extracellular vesicles, urine samples underwent differential centrifugation by a micro-centrifuge at 10000×g for 10 minutes at 4°C. The supernatant was then filtered through a 0.22-µm filter to eliminate bacteria and foreign particles. For DNA extraction, isolated extracellular vesicles were boiled at 100°C for 40 minutes and centrifuged at 13000 rpm for 30 minutes at 4°C to eliminate the remaining floating particles and waste. Subsequently, the supernatant was collected and subjected to DNA isolation using a FastDNA® SPIN Kit for Soil (MP Biomedicals, Solon, OH, USA) according to the standard protocol for DNA extraction. The DNA in each sample was quantified using an Epoch™ Spectrophotometer system (BioTek Instruments, Winooski, VT, USA).

16S rDNA sequencing and taxonomic assignment

Bacterial genomic DNA PCR amplification was executed with primers specific for V3-V4 hypervariable regions of the 16S rDNA gene. The amplicons were pooled, and the sequencing was carried out at ChunLab, Inc. (Seoul, Korea), with a MiSeq Sequencing system (Illumina Inc., San Diego, CA, USA) according to the manufacturer’s instructions.

Raw reads were processed with quality check and filtering of low quality (<Q25) reads by Trimmmomatic 0.32. After passing quality control, paired-end sequence data were merged together using PANDaSeq.14 Primers were then trimmed with a ChunLab in-house program at a similarity cut off of 0.8. Non-specific amplicons that do not encode 16S rRNA were detected by HMMER’s hmmsearch program15 with 16S rRNA profiles. Sequences were denoised using DUDE-Seq16 and non-redundant reads were extracted by UCLUST-clustering.17 The EzBioCloud database was used for taxonomic assignment using USEARCH (8.1.1861_i86linux32),17 followed by more precise pairwise alignment.18 UCHIME19 and the non-chimeric 16S rRNA database from EzBioCloud were used to detect chimera on reads that contained a less than 97% best hit similarity rate. Sequence data were then clustered using CD-HIT10 and UCLUST.17 The alpha diversity indices and rarefaction curves were estimated in-house code.

Urine phthalate

For analysis of monophthalates, we focused on mono-n-butylphthalate, mono-(2-ethyl-5-hydroxyhexyl) phthalate, mono-(2-ethyl-5-oxohexyl) phthalate, mono-(2-ethyl-5-carboxylpentyl) phthalate, and mono-benzylphthalate, which are widely used metabolites of di-n-butyl phthalate (DnBP), di(2-ethylhexyl) phthalate (DEHP), and butylbenzyl phthalate (BBzP). After collection, urine specimens were frozen at -70°C until analyzed. Samples were thawed at room temperature before pretreatment. In an 8-mL glass vial, 1 mL of 2 M sodium acetate and 20 µL of β-glucuronidase were added to 500 µL of each urine sample. After vortexing for 10 minutes using a large vortexer, the mixture was incubated at 37°C for 16 hours to hydrolyze the phthalate metabolite complexes. After adding 100 µL of 2 M HCl, 50 µL of internal standard, and 4 mL of ethyl acetate and vortexing for 15 minutes, the solution was centrifuged for 5 minutes at 3000 rpm. The supernatant was collected for analysis, with care being taken not to disturb the solid at the bottom of the tube. The quantity of phthalate metabolites in the samples was measured using LC-MS/MS.

Statistical analysis

All data analysis was performed using the one-way ANOVA procedure in Statistical Analysis System (SAS), version 9.4 (SAS Institute Inc., Cary, NC, USA), at a 95% confidence level.

Ethical consideration

This clinical study was approved by the Research Ethics Committee of Inha University Hospital (IRB No. 2018-07-007), and written consent was obtained from the legal guardians of all participants.

RESULTS

A total of 30 children were randomized and evenly assigned to two groups. All of them completed the study without any complications. The mean age of the enrolled patients was 9.20±1.98 years (minimum–maximum age: 6.08–12.41 years). Baseline characteristics, including sex, age, height, weight, body mass index, FeNO, forced expiratory volume in 1 second (FEV1), immunoglobulin E (IgE), and allergen sensitization, are summarized in Table 1 and Supplementary Table 4 (only online).

Indoor air pollutant concentration

PM2.5 and CO2 concentrations were measured to assess indoor air pollution. The mean levels of PM2.5 were 17 µg/m³ with the filter off and 9.26 µg/m³ with the filter on, indicating a statistically significant decrease when the air purifier was used (p < 0.001) (Table 2). However, CO2 concentration, relative humidity, and temperature showed no significant differences depending on air purifier use (Supplementary Table 5, only online).

Asthma symptoms, medication use, and PEFR

Symptom scores were 14.03 in the filter-off condition and 13.97 in the filter-on condition, with no significant difference between the two (Table 3). Medication scores were 6.9 in the fil-

https://doi.org/10.3349/ymj.2020.61.4.310
The ter-off condition and 7.12 in the filter-on condition, reflecting a statistically significant decrease in the use of anti-asthmatic medications when the air purifier was used ($p < 0.001$) (Table 3). PEFRs were 326.24 L/min in the filter-off condition and 321.33 L/min in the filter-on condition, which was not a statistically significant difference (Table 4).

FeNO, urine microbiome, and urine phthalate

FeNO levels were 27.76 ppb in the filter-off condition and 28.5 ppb in the filter-on condition, which was not a statistically significant difference (Table 4). Bacterial richness, as determined using the Chao 1 index, was markedly lower in the filter-on condition than in the filter-off condition (Fig. 2). No significant difference in the diversity of bacterial extracellular vesicles between the filter-on and -off conditions was observed under principal component analysis (Fig. 3). The concentration of phthalate metabolites also showed no significant difference between the two (Table 5).
MnBP, mono-n-butylphthalate; MBzP, mono-benzylphthalate; MEHHP, mono-(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, mono-(2-ethyl-5-oxohexyl) phthalate; MECCP, mono-(2-ethyl-5-carboxypentyl) phthalate.

Table 5. Concentration of Urine Phthalate with the Filter OFF or ON

<table>
<thead>
<tr>
<th>Variable</th>
<th>Filter OFF</th>
<th>Filter ON</th>
<th>( p ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>MnBP (ng/mL)</td>
<td>58.2±44.9</td>
<td>46.4±26.9</td>
<td>0.221</td>
</tr>
<tr>
<td>MBzP (ng/mL)</td>
<td>7.4±7.0</td>
<td>10.9±24.5</td>
<td>0.450</td>
</tr>
<tr>
<td>MEHHP (ng/mL)</td>
<td>36.7±19.4</td>
<td>44.0±33.7</td>
<td>0.308</td>
</tr>
<tr>
<td>MEOHP (ng/mL)</td>
<td>55.1±13.0</td>
<td>27.9±21.2</td>
<td>0.303</td>
</tr>
<tr>
<td>MECCP (ng/mL)</td>
<td>55.1±25.9</td>
<td>61.1±34.8</td>
<td>0.446</td>
</tr>
</tbody>
</table>

In the present study, we documented a significant reduction in indoor PM\(_{2.5}\) levels and improvement in medication scores. While the outdoor temperature and air pollutants might have differed during the cross-over period, the study was conducted under the same conditions during this period, and thus, the difference in outdoor atmospheric factors would not have affected the study outcomes. In addition, since the basal PM\(_{2.5}\) value was higher than that in the study mentioned above, the decrease in PM\(_{2.5}\) values after use of the air purifier is more meaningful. Moreover, the decrease in the frequency of medication used was significant since the placebo effect was excluded through the single blind and cross-over study design with a sample size of 30 people.

There is a hygiene hypothesis that suggests that decreased microbiome diversity is an environmental cause of increased asthma prevalence. Although the exact mechanism by which PM\(_{2.5}\) exposure perturbs airway microbiome is unknown, it has been found that individuals with better lung function have greater airway bacteria diversity in the bronchial tree. In support thereof, previous studies in patients with respiratory or allergic diseases have consistently shown reduced airway microbiome diversity and increased total richness. In our study, there was a significant decrease in urine microbiome richness in the filter-on condition, while there was no significant difference in urine bacterial diversity. Also, another study demonstrated that the number of airborne fungi decreases when an air purifier fan is on. These results suggest that air purifiers are beneficial to asthma patients by reducing total microbiome burden. Accordingly, we suggest that the urine microbiome burden is significantly reduced with the use of an air purifier to filter out and reduce the number and volume of bacteria in indoor air.

PM\(_{2.5}\) is known to penetrate the vascular and lymphatic systems after inhalation and to be strongly associated with respiratory and allergic diseases. Moreover, a significant association between short-term PM exposure and asthma-related hospital visits has been demonstrated. Accordingly, reducing indoor exposure to PM\(_{2.5}\) may be beneficial to asthma management. The results of this study showed that the use of an air purifier for 3 weeks significantly decreased indoor PM\(_{2.5}\) levels, thereby reducing the frequency of medication use and urine microbiome burden in children with asthma.

As of now, the role of an air purifier in allergic disease prevention continues to be debated. While a number of studies have evaluated the impact of air purifiers on allergic disease, many are limited by small sample sizes and inadequate blinding. A study funded by Samsung Electronics Co., Ltd demonstrated that reducing indoor PM\(_{2.5}\) levels with air purifiers improved childhood asthma control test scores and mean evening peak flow rates. However, since the city where the study was conducted had a very low basal PM\(_{2.5}\) level of 7.42 µg/m\(^3\), and the decrease in PM\(_{2.5}\) values after use of the air purifier is more meaningful. Moreover, the decrease in the frequency of medication used was significant since the placebo effect was excluded through the single blind and cross-over study design with a sample size of 30 people.

In conclusion, we found that the indoor PM\(_{2.5}\) concentrations significantly decreased through the use of air purifier for 3 weeks, thereby reducing the frequency of medications used and significantly reducing the urine microbiome burden in children. 

**DISCUSSION**
children with asthma. We concluded that air purifiers can have a positive effect on the health of asthma patients by filtering fine dust and microbes from indoor air. This study can be used as basic data for further studies in the future, given that it is the first study in Korea on the effects of using air purifiers on children with asthma.

ACKNOWLEDGEMENTS

This study was supported by the Korea Environmental Industry and Technology Institutes and the Korea Ministry of Environment.

AUTHOR CONTRIBUTIONS

Conceptualization: Dae Hyun Lim. Data curation: Sungroul Kim and Dae Hyun Lim. Formal analysis: Ga Hee Lee, Sungroul Kim, and Dae Hyun Lim. Funding acquisition: Sungroul Kim and Dae Hyun Lim. Investigation: Sangwoon Lee, Sungroul Kim, and Dae Hyun Lim. Methodology: Sungroul Kim and Dae Hyun Lim. Project administration: Dae Hyun Lim. Resources: Jeong Hee Kim and Dae Hyun Lim. Software: Ga Hee Lee, Sangwoon Lee, Sungroul Kim, and Dae Hyun Lim. Supervision: Dae Hyun Lim. Validation: Sungroul Kim, Jeong Hee Kim, and Dae Hyun Lim. Visualization: Sungroul Kim and Dae Hyun Lim. Writing—original draft: Ga Hee Lee and Dae Hyun Lim. Writing—review & editing: Ga Hee Lee and Dae Hyun Lim. Approval of final manuscript: all authors.

ORCID iDs

Ga Hee Lee https://orcid.org/0000-0002-9766-7914
Jeong Hee Kim https://orcid.org/0000-0002-7054-8552
Sungroul Kim https://orcid.org/0000-0001-8726-9288
Sangwoon Lee https://orcid.org/0000-0001-7158-8786
Dae Hyun Lim https://orcid.org/0000-0002-4558-3284

REFERENCES


